Analysts Have Conflicting Sentiments on These Healthcare Companies: Nektar Therapeutics (NKTR), Catalent (CTLT) and Elevation Oncology (ELEV)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nektar Therapeutics (NKTR – Research Report), Catalent (CTLT – Research Report) and Elevation Oncology (ELEV – Research Report).

Nektar Therapeutics (NKTR)

Nektar Therapeutics received a Sell rating from J.P. Morgan analyst Jessica Fye yesterday. The company’s shares closed last Tuesday at $4.03, close to its 52-week low of $3.02.

According to TipRanks.com, Fye is a 4-star analyst with an average return of 8.2% and a 51.2% success rate. Fye covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Crinetics Pharmaceuticals, and Intra-Cellular Therapies.

The word on The Street in general, suggests a Hold analyst consensus rating for Nektar Therapeutics with a $5.23 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Catalent (CTLT)

In a report released yesterday, Julia Qin from J.P. Morgan maintained a Buy rating on Catalent, with a price target of $130.00. The company’s shares closed last Tuesday at $89.28, close to its 52-week low of $86.34.

According to TipRanks.com, Qin is a 3-star analyst with an average return of 7.3% and a 55.0% success rate. Qin covers the Healthcare sector, focusing on stocks such as Singular Genomics Systems, Pacific Biosciences, and Akoya Biosciences.

Catalent has an analyst consensus of Strong Buy, with a price target consensus of $119.38, representing a 29.6% upside. In a report released yesterday, Barclays also maintained a Buy rating on the stock with a $115.00 price target.

Elevation Oncology (ELEV)

Elevation Oncology received a Hold rating from J.P. Morgan analyst Anupam Rama yesterday. The company’s shares closed last Tuesday at $1.15, close to its 52-week low of $1.12.

According to TipRanks.com, Rama is a 3-star analyst with an average return of 1.6% and a 44.9% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Springworks Therapeutics, and Apellis Pharmaceuticals.

Currently, the analyst consensus on Elevation Oncology is a Moderate Buy with an average price target of $11.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NKTR:

• Analysts Offer Insights on Consumer Goods Companies: Foot Locker (FL), Shift Technologies (SFT) and Hyzon Motors (HYZN)
• Analysts Conflicted on These Technology Names: Diebold Nixdorf (DBD), Itron (ITRI) and BAE Systems (OtherBAESF)
• Mobiquity Technologies Selected by Endorse to Execute Marketing and Advisory Services for the Crypto, NFT, Gaming and Web3 Markets
• These Stocks Are the Biggest Pre-Market Movers on Wednesday
• FangDD Announces Board and Management Changes